Abdera Therapeutics
PrivateLast Round
Series B
Apr 20, 2023
Total Funding Raised
$148.8M
Company Overview
Abdera Therapeutics operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Series B round in April 2023.
Abdera Therapeutics is a biotechnology company that develops a precision oncology platform for targeted alpha radiation therapies aimed at patients with relapsed, refractory, and metastatic cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Abdera Therapeutics Comparables
Compare Abdera Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alpha-9 Oncology | 87% | |
| Radionetics Oncology | 87% | |
| Ratio Therapeutics Inc. | 84% |
For institutional investors. Book with your work email.
Abdera Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 20, 2023 | ||||
| Seed | Jan 14, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Abdera Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Amplitude Ventures | Series B, Series A |
| Versant Ventures | Series B, Series A |
| Viking Global Investors | Series B |
| venBio | Series B |
| Qiming | Series B |
| Northview LifeSciences | Series A, Series B |
| RTW Investments | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 13, 2026
Presenting at the 44th Annual J.P. Morgan Healthcare Conference.
- Aug 26, 2025
Initial Phase 1 data for ABD-147 presented at IASLC 2025.
For institutional investors. Book with your work email.
Abdera Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Abdera Therapeutics's valuation, stock price, and market status.
Is Abdera Therapeutics a public or private company?
Abdera Therapeutics is a private company.
What is the current stock price of Abdera Therapeutics?
Abdera Therapeutics is a private company, so its shares have no public market price. Caplight tracks Abdera Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Abdera Therapeutics worth (valuation)?
Valuation information for Abdera Therapeutics is not publicly available.
Can I buy Abdera Therapeutics stock?
Abdera Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Abdera Therapeutics's last funding round?
Abdera Therapeutics's most recent funding round was Series B on April 20, 2023.
Who are the main investors in Abdera Therapeutics?
Key investors in Abdera Therapeutics include Amplitude Ventures, Versant Ventures, venBio.
Will Abdera Therapeutics IPO soon?
No public IPO plans have been announced for Abdera Therapeutics.
How can I track Abdera Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Abdera Therapeutics's shares on secondary markets.